Chapter 24 : Hepatitis A Virus

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.

Ebook: Choose a downloadable PDF or ePub file. Chapter is a downloadable PDF file. File must be downloaded within 48 hours of purchase

Buy this Chapter
Digital (?) $15.00

Preview this chapter:
Zoom in

Hepatitis A Virus, Page 1 of 2

| /docserver/preview/fulltext/10.1128/9781555816698/9781555816032_Chap24-1.gif /docserver/preview/fulltext/10.1128/9781555816698/9781555816032_Chap24-2.gif


The most common clinical manifestation of hepatitis A virus (HAV) infection is acute hepatitis, which typically presents with rapid onset of nausea, loss of appetite, fever, abdominal pain, dark urine, and jaundice. Importantly, HAV causes only acute hepatitis, and long-term persistent infection has never been well documented or clearly associated with chronic liver disease. The internal ribosome entry site (IRES) structure is unique, but overall resembles the aphthovirus IRES more than the enterovirus IRES. Importantly, the HAV IRES is distinguished from other picornaviral IRES elements by its apparent requirement for all eukaryotic translation initiation factors, including intact eIF- 4G, to direct internal entry of the 40S ribosome on the viral RNA. In vivo, the virus is thought to replicate primarily within hepatocytes. The infecting HAV particle presumably arrives at the basolateral membrane surface of the hepatocyte, within the space of Disse, via the portal circulation from the intestines and diffusion through the hepatic sinusoids. Viremia is present throughout much of the incubation period and into the acute phase of illness but is reduced in magnitude (as is the fecal shedding of virus) with the onset of hepatitis and the appearance of antibodies to HAV.

Citation: Feng Z, Lemon S. 2010. Hepatitis A Virus, p 383-396. In Ehrenfeld E, Domingo E, Roos R (ed), The Picornaviruses. ASM Press, Washington, DC. doi: 10.1128/9781555816698.ch24
Highlighted Text: Show | Hide
Loading full text...

Full text loading...


Image of Figure 1.
Figure 1.

Histopathologic abnormalities in the liver of a patient with acute HAV infection. There is extensive inflammation of the portal and periportal areas by lymphocytes and other small, mononuclear cells (upper right field) and moderate loss of the normal hepatic architecture with lobular disarray (lower left field). There is also prominent hepatocellular ballooning degeneration (cytoplasmic vacuolization). Hematoxylin and eosin stain was used. Original magnification, ×40. (Image reproduced with permission of the publisher from Martin and Lemon [ ] and originally provided by S.-Y. Xiao.)

Citation: Feng Z, Lemon S. 2010. Hepatitis A Virus, p 383-396. In Ehrenfeld E, Domingo E, Roos R (ed), The Picornaviruses. ASM Press, Washington, DC. doi: 10.1128/9781555816698.ch24
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of Figure 2.
Figure 2.

Acute HAV infection in a New World owl monkey challenged by intravenous inoculation with 4.10 log focus-forming units of a cell culture-derived but still virulent virus ( ). Viremia ( ), fecal virus shedding ( ), and intrahepatic virus titer ( ) were determined by virus isolation in cell culture. The antibody response to the infection was measured by an isotypenonspecific competitive inhibition immunoassay. After several weeks of intense fecal virus shedding, biochemical evidence of liver injury (ALT elevations) developed simultaneously with the appearance of HAV-specific antibody and termination of virus replication.

Citation: Feng Z, Lemon S. 2010. Hepatitis A Virus, p 383-396. In Ehrenfeld E, Domingo E, Roos R (ed), The Picornaviruses. ASM Press, Washington, DC. doi: 10.1128/9781555816698.ch24
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of Figure 3.
Figure 3.

Organization of the ˜7.2-kb HAV genome. The open reading frame is shown as a box, flanked by the 5′ and 3′ UTRs, which contain an IRES and a poly(A) tail, respectively. The sites of polyprotein cleavage occurring during processing are indicated, with the arrow marking the primary cleavage at the 2A-2B junction. Shown below the genome is an expanded view of the structural proteins. All processing events with the exception of the VP0 (VP4-VP2) maturation cleavage ( ) and PX (VP1-2A) cleavage (*) are mediated by 3C, a cysteine protease and the only protease expressed by the virus. The PX cleavage gives rise to mature VP1 protein with heterogenous carboxyl termini, and the reaction is catalyzed by an unknown cellular protease.

Citation: Feng Z, Lemon S. 2010. Hepatitis A Virus, p 383-396. In Ehrenfeld E, Domingo E, Roos R (ed), The Picornaviruses. ASM Press, Washington, DC. doi: 10.1128/9781555816698.ch24
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of Figure 4.
Figure 4.

HAV infection of FRhK-4 cells disrupts signal transduction from RLR pathogen recognition receptors. Cells, either uninfected or infected for 3 days with HM175/18f virus at a multiplicity of infection of 1, were transfected with luciferase reporter plasmids for IFN-β (left panel; IRF-3-responsive) and PRD-II (right panel; NF-κB-responsive) promoter elements and then either mock challenged (open bars) or challenged with Sendai virus (solid bars), a robust agonist of RIG-I-mediated IFN responses. Sendai virus gene expression is not inhibited by HAV infection. (Reproduced from [ ] with permission. Copyright 2007, National Academy of Sciences, USA.)

Citation: Feng Z, Lemon S. 2010. Hepatitis A Virus, p 383-396. In Ehrenfeld E, Domingo E, Roos R (ed), The Picornaviruses. ASM Press, Washington, DC. doi: 10.1128/9781555816698.ch24
Permissions and Reprints Request Permissions
Download as Powerpoint


1. Advisory Committee on Immunization Practices. 2007. Update: prevention of hepatitis A after exposure to hepatitis A virus and in international travelers. Updated recommendations. Morb. Mortal. Wkly. Rep. 56:10801084.
2. Advisory Committee on Immunization Practices, A. E. Fiore,, A. Wasley, and, B. P. Bell. 2006. Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep. 55:123.
3. Anderson, D. A., and, B. C. Ross. 1990. Morphogenesis of hepatitis A virus: isolation and characterization of subviral particles. J. Virol. 64:52845289.
4. Ank, N., and, S. R. Paludan. 2009. Type III IFNs: new layers of complexity in innate antiviral immunity. BioFactors 35:8287.
5. Asher, L. V.,, L. N. Binn, and, R. H. Marchwicki. 1987. Demonstration of hepatitis A virus in cell culture by electron microscopy with immunoperoxidase staining. J. Virol. Methods 15:323328.
6. Asher, L. V. S.,, L. N. Binn,, T. L. Mensing,, R. H. Marchwicki,, R. A. Vassell, and, G. D. Young. 1995. Pathogenesis of hepatitis A in orally inoculated owl monkeys ( Aotus trivergatus). J. Med. Virol. 47:260268.
7. Binn, L. N.,, W. H. Bancroft,, S. M. Lemon,, R. H. Marchwicki,, J. W. LeDuc,, C. J. Trahan,, E. C. Staley, and, C. M. Keenan. 1986. Preparation of a prototype inactivated hepatitis A virus vaccine from infected cell cultures. J. Infect. Dis. 153:749756.
8. Bishop, N. E., and, D. A. Anderson. 1997. Hepatitis A virus subviral particles: purification, accumulation, and relative infectivity of virions, provirions and procapsids. Arch. Virol. 142:21472160.
9. Bishop, N. E., and, D. A. Anderson. 1993. RNA-dependent cleavage of VPO capsid protein in provirions of hepatitis A virus. Virology 197:616623.
10. Blank, C. A.,, D. A. Anderson,, M. Beard, and, S. M. Lemon. 2000. Infection of polarized cultures of human intestinal epithelial cells with hepatitis A virus: vectorial release of progeny virions through apical cellular membranes. J. Virol. 74:64766484.
11. Borman, A. M., and, K. M. Kean. 1997. Intact eukaryotic initiation factor 4G is required for hepatitis A virus internal initiation of translation. Virology 237:129136.
12. Bower, W. A.,, O. V. Nainan,, X. Han, and, H. S. Margolis. 2000. Duration of viremia in hepatitis A virus infection. J. Infect. Dis. 182:1217.
13. Brack, K.,, I. Berk,, T. Magulski,, J. Lederer,, A. Dotzauer, and, A. Vallbracht. 2002. Hepatitis A virus inhibits cellular antiviral defense mechanisms induced by double-stranded RNA. J. Virol. 76:1192011930.
14. Brack, K.,, W. Frings,, A. Dotzauer, and, A. Vallbracht. 1998. A cytopathogenic, apoptosis-inducing variant of hepatitis A virus. J. Virol. 72:33703376.
15. Brown, E. A.,, S. P. Day,, R. W. Jansen, and, S. M. Lemon. 1991. The 5′ nontranslated region of hepatitis A virus: secondary structure and elements required for translation in vitro. J. Virol. 65:58285838.
16. Chang, K. H.,, E. A. Brown, and, S. M. Lemon. 1993. Cell type-specific proteins which interact with the 5′ nontranslated region of hepatitis A virus RNA. J. Virol. 67:67166725.
17. Cho, M. W., and, E. Ehrenfeld. 1991. Rapid completion of the replication cycle of hepatitis A virus subsequent to reversal of guanidine inhibition. Virology 180:770780.
18. Cockayne, E. A. 1912. Catarrhal jaundice, sporadic and epidemic, and its relation to acute yellow atrophy of the liver. Q. J. Med. 6:129.
19. Cohen, J. I.,, S. Feinstone, and, R. H. Purcell. 1989. Hepatitis A virus infection in a chimpanzee: duration of viremia and detection of virus in saliva and throat swabs. J. Infect. Dis. 160:887890.
20. Cohen, J. I.,, J. R. Ticehurst,, S. M. Feinstone,, B. Rosenblum, and, R. H. Purcell. 1987. Hepatitis A virus cDNA and its RNA transcripts are infectious in cell culture. J. Virol. 61:30353039.
21. Cohen, L.,, D. Benichou, and, A. Martin. 2002. Analysis of deletion mutants indicates that the 2A polypeptide of hepatitis A virus participates in virion morphogenesis. J. Virol. 76:74957505.
22. Crispe, I. N. 2009. The liver as a lymphoid organ. Annu. Rev. Immunol. 27:147163.
23. Dienstag, J. L.,, S. M. Feinstone,, R. H. Purcell,, J. H. Hoofnagle,, L. F. Barker,, W. T. London,, H. Popper,, J. M. Peterson, and, A. Z. Kapikian. 1975. Experimental infection of chimpanzees with hepatitis A virus. J. Infect. Dis. 132:532545.
24. Dotzauer, A.,, U. Gebhardt,, K. Bieback,, U. Göttke,, A. Kracke,, J. Mages,, S. M. Lemon, and, A. Vallbracht. 2000. Hepatitis A virus-specific immunoglobulin A mediates infection of hepatocytes with hepatitis A virus via the asialoglycoprotein receptor. J. Virol. 74:1095010957.
25. Eisenbach, C.,, T. Longerich,, H. Fickenscher,, G. Schalasta,, W. Stremmel, and, J. Encke. 2006. Recurrence of clinically significant hepatitis A following liver transplantation for fulminant hepatitis A. J. Clin. Virol. 35:109112.
26. Emerson, S. U.,, Y. K. Huang, and, R. H. Purcell. 1993. 2B and 2C mutations are essential but mutations throughout the genome of HAV contribute to adaptation to cell culture. Virology 194:475480.
27. Endo, K.,, M. Takahashi,, K. Masuko,, K. Inoue,, Y. Akahane, and, H. Okamoto. 2007. Full-length sequences of subgenotype IIIA and IIIB hepatitis A virus isolates: characterization of genotype III HAV genomes. Virus Res. 126:116127.
28. Feigelstock, D.,, P. Thompson,, P. Mattoo,, Y. Zhang, and, G. G. Kaplan. 1998. The human homolog of HAVcr-1 codes for a hepatitis A virus cellular receptor. J. Virol. 72:66216628.
29. Feinstone, S. M.,, A. Z. Kapikian, and, R. H. Purcell. 1973. Hepatitis A: detection by immune electron microscopy of a viruslike antigen associated with acute illness. Science 182:10261028.
30. Fensterl, V.,, D. Grotheer,, I. Berk,, S. Schlemminger,, A. Vall-bracht, and, A. Dotzauer. 2005. Hepatitis A virus suppresses RIG-I-mediated IRF-3 activation to block induction of beta interferon. J. Virol. 79:1096810977.
31. Fleischer, B.,, S. Fleischer,, K. Maier,, K. H. Wiedmann,, M. Sacher,, H. Thaler, and, A. Vallbracht. 1990. Clonal analysis of infiltrating T lymphocytes in liver tissue in viral hepatitis A. Immunology 69:1419.
32. Funkhouser, A. W.,, R. H. Purcell,, E. D’Hondt, and, S. U. Emerson. 1994. Attenuated hepatitis A virus: genetic determinants of adaptation to growth in MRC-5 cells. J. Virol. 68:148157.
33. Glikson, M.,, E. Galun,, R. Oren,, R. Tur-Kaspa, and, D. Shouval. 1992. Relapsing hepatitis A. Review of 14 cases and literature survey. Medicine 71:1423.
34. Gordon, S. C.,, K. R. Reddy,, L. Schiff, and, E. R. Schiff. 1984. Prolonged intrahepatic cholestasis secondary to acute hepatitis A. Ann. Intern. Med. 101:635637.
35. Gosert, R.,, K. H. Chang,, R. Rijnbrand,, M. Yi,, D. V. Sangar, and, S. M. Lemon. 2000. Transient expression of cellular polypyrimidine-tract binding protein stimulates cap-independent translation directed by both picornaviral and flaviviral internal ribosome entry sites in vivo. Mol. Cell. Biol. 20:15831595.
36. Gosert, R.,, D. Egger, and, K. Bienz. 2000. A cytopathic and a cell culture adapted hepatitis A virus strain differ in cell killing but not in intracellular membrane rearrangements. Virology 266:157169.
37. Graff, J.,, J. Cha,, L. B. Blyn, and, E. Ehrenfeld. 1998. Interaction of poly(rC) binding protein 2 with the 5′ noncoding region of hepatitis A virus RNA and its effects on translation. J. Virol. 72:96689675.
38. Graff, J.,, O. C. Richards,, K. M. Swiderek,, M. T. Davis,, F. Rusnak,, S. A. Harmon,, X. Y. Jia,, D. F. Summers, and, E. Ehrenfeld. 1999. Hepatitis A virus capsid protein VP1 has a heterogeneous C terminus. J. Virol. 73:60156023.
39. Gust, I. D.,, N. I. Lehmann, and, M. Dimitrakakis. 1979. A seroepidemiologic study of infection with HAV and HBV in five Pacific islands. Am. J. Epidemiol. 110:237242.
40. Havens, W. P., Jr. 1945. Experiment in cross immunity between infectious hepatitis and homologous serum jaundice. Proc. Soc. Exp. Biol. Med. 59:148150.
41. Innis, B. L.,, R. Snitbhan,, P. Kunasol,, T. Laorakpongse,, W. Poopatanakool,, C. A. Kozik,, S. Suntayakorn,, T. Suknuntapong,, A. Safary,, D. B. Tang, et al. 1994. Protection against hepatitis A by an inactivated vaccine. JAMA 271:13281334.
42. Inoue, K.,, M. Yoshiba,, H. Yotsuyanagi,, T. Otsuka,, H. Sekiyama, and, R. Fujita. 1996. Chronic hepatitis A with persistent viral replication. J. Med. Virol. 50:322324.
43. Kaplan, G.,, A. Totsuka,, P. Thompson,, T. Akatsuka,, Y. Moritsugu, and, S. M. Feinstone. 1996. Identification of a surface glycoprotein on African green monkey kidney cells as a receptor for hepatitis A virus. EMBO J. 15:42824296.
44. Karayiannis, P.,, M. J. McGarvey,, M. A. Fry,, H. C. Thomas, and, A. J. Zuckerman. 1988. Detection of hepatitis A virus RNA in tissues and faeces of experimentally infected tamarins by cDNA-RNA hybridisation, p. 117–120. In A. J. Zuckerman (ed.), Viral Hepatitis and Liver Disease. Alan R. Liss, Inc., New York, NY.
45. Kato, H.,, O. Takeuchi,, S. Sato,, M. Yoneyama,, M. Yamamoto,, K. Matsui,, S. Uematsu,, A. Jung,, T. Kawai,, K. J. Ishii,, O. Yamaguchi,, K. Otsu,, T. Tsujimura,, C. S. Koh,, C. Reis e Sousa,, Y. Matsuura,, T. Fujita, and, S. Akira. 2006. Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature 441:101105.
46. Kohl, I.,, V. Nemecek,, M. Summerová,, R. Chlíbek,, K. Nad’ová, and, O. Mináriková. 2006. Long-term protective effect of post-exposure Havrix administration during viral hepatitis type A outbreaks. Eur. J. Epidemiol. 21:893899.
47. Kurane, I.,, L. N. Binn,, W. H. Bancroft, and, F. A. Ennis. 1985. Human lymphocyte responses to hepatitis A virus-infected cells: interferon production and lysis of infected cells. J. Immunol. 135:21402144.
48. LeDuc, J. W.,, S. M. Lemon,, C. M. Keenan,, R. R. Graham,, R. H. Marchwicki, and, L. N. Binn. 1983. Experimental infection of the New World owl monkey (Aotus trivirgatus) with hepatitis A virus. Infect. Immun. 40:766772.
49. Lemon, S. M. 1985. Type A viral hepatitis: new developments in an old disease. N. Engl. J. Med. 313:10591067.
50. Lemon, S. M.,, E. Amphlett, and, D. Sangar. 1991. Protease digestion of hepatitis A virus: disparate effects on capsid proteins, antigenicity, and infectivity. J. Virol. 65:56365640.
51. Lemon, S. M., and, L. N. Binn. 1983. Serum neutralizing antibody response to hepatitis A virus. J. Infect. Dis. 148:10331039.
52. Lemon, S. M.,, L. N. Binn,, R. Marchwicki,, P. C. Murphy,, L. H. Ping,, R. W. Jansen,, L. V. S. Asher,, J. T. Stapleton,, D. G. Taylor, and, J. W. LeDuc. 1990. In vivo replication and reversion to wild-type of a neutralization-resistant variant of hepatitis A virus. J. Infect. Dis. 161:713.
53. Lemon, S. M.,, P. C. Murphy,, P. J. Provost,, I. Chalikonda,, J. P. Davide,, T. L. Schofield,, D. R. Nalin, and, J. A. Lewis. 1997. Immunoprecipitation and virus neutralization assays demonstrate qualitative differences between protective antibody responses to inactivated hepatitis A vaccine and passive immunization with immune globulin. J. Infect. Dis. 176:919.
54. Lemon, S. M.,, P. C. Murphy,, P. A. Shields,, L. H. Ping,, S. M. Feinstone,, T. Cromeans, and, R. W. Jansen. 1991. Antigenic and genetic variation in cytopathic hepatitis A virus variants arising during persistent infection: evidence for genetic recombination. J. Virol. 65:20562065.
55. Lemon, S. M., and, C. N. Shapiro. 1994. The value of immunization against hepatitis A. Infect. Agents Dis. 3:3849.
56. Li, K.,, Z. Chen,, N. Kato,, M. Gale, Jr., and, S. M. Lemon. 2005. Distinct poly-I:C and virus-activated interferon signaling pathways in hepatocytes. J. Biol. Chem 280:1673916747.
57. Maier, K.,, P. Gabriel,, E. Koscielniak,, Y. D. Stierhof,, K. H. Wiedmann,, B. Flehmig, and, A. Vallbracht. 1988. Human gamma interferon production by cytotoxic T lymphocytes sensitized during hepatitis A virus infection. J. Virol. 62:37563763.
58. Mao, J. S.,, Y. Y. Go,, H. Y. Huang,, P. H. Yu,, B. Z. Huang,, Z. S. Ding,, N. L. Chen,, J. H. Yu, and, R. Y. Xie. 1981. Susceptibility of monkeys to human hepatitis A virus. J. Infect. Dis. 144:5560.
59. Margolis, H. S., and, O. V. Nainan. 1990. Identification of virus components in circulating immune complexes isolated during hepatitis A virus infection. Hepatology 11:3137.
60. Martin, A.,, D. Benichou,, S. F. Chao,, L. M. Cohen, and, S. M. Lemon. 1999. Maturation of the hepatitis A virus capsid protein VP1 is not dependent on processing by the 3Cpro proteinase. J. Virol. 73:62206227.
61. Martin, A., and, S. M. Lemon. 2006. Hepatitis A virus: from discovery to vaccines. Hepatology 43:S164S172.
62. Martin, A., and, S. M. Lemon. 2002. The molecular biology of hepatitis A virus, p. 23–50. In J. Ou (ed.), Hepatitis Viruses. Kluwer Academic Publishers, Norwell, MA.
63. Mathiesen, L. R.,, J. Drucker,, D. Lorenz,, J. Wagner,, R. J. Gerety, and, R. H. Purcell. 1978. Localization of hepatitis A antigen in marmoset organs during acute infection with hepatitis A virus. J. Infect. Dis. 138:369377.
64. Meyers, J. H.,, C. A. Sabatos,, S. Chakravarti, and, V. K. Kuchroo. 2005. The TIM gene family regulates autoimmune and allergic diseases. Trends Mol. Med. 11:362369.
65. Mourani, S.,, S. S. M. Dobbs,, R. M. Genta,, A. K. Tandon, and, B. Yoffe. 1994. Hepatitis A virus-associated cholecystitis. Ann. Intern. Med. 120:398400.
66. Nainan, O. V.,, H. S. Margolis,, B. H. Robertson,, M. Balayan, and, M. A. Brinton. 1991. Sequence analysis of a new hepatitis A virus naturally infecting cynomolgus macaques ( Macaca fascicularis). J. Gen. Virol. 72:16851689.
67. Najarian, R.,, D. Caput,, W. Gee,, S. J. Potter,, A. Renard,, J. Merryweather,, G. Van Nest, and, D. Dina. 1985. Primary structure and gene organization of human hepatitis A virus. Proc. Natl. Acad. Sci. USA 82:26272631.
68. Normann, A.,, C. Jung,, A. Vallbracht, and, B. Flehmig. 2004. Time course of hepatitis A viremia and viral load in the blood of human hepatitis A patients. J. Med. Virol. 72:1016.
69. Ping, L. H.,, R. W. Jansen,, J. T. Stapleton,, J. I. Cohen, and, S. M. Lemon. 1988. Identification of an immunodominant antigenic site involving the capsid protein VP3 of hepatitis A virus. Proc. Natl. Acad. Sci. USA 85:82818285.
70. Ping, L. H., and, S. M. Lemon. 1992. Antigenic structure of human hepatitis A virus defined by analysis of escape mutants selected against murine monoclonal antibodies. J. Virol. 66:22082216.
71. Probst, C.,, M. Jecht, and, V. Gauss-Müller. 1998. Processing of proteinase precursors and their effect on hepatitis A virus particle formation. J. Virol. 72:80138020.
72. Probst, C.,, M. Jecht, and, V. Gauss-Müller. 1999. Intrinsic signals for the assembly of hepatitis A virus particles. Role of structural proteins VP4 and 2A. J. Biol. Chem. 274:45274531.
73. Provost, P. J.,, P. A. Conti,, P. A. Giesa,, F. S. Banker,, E. B. Buynak,, W. J. McAleer, and, M. R. Hilleman. 1983. Studies in chimpanzees of live, attenuated hepatitis A vaccine candidates. Proc. Soc. Exp. Biol. Med. 172:357363.
74. Provost, P. J., and, M. R. Hilleman. 1979. Propagation of human hepatitis A virus in cell culture in vitro. Proc. Soc. Exp. Biol. Med. 160:213221.
75. Provost, P. J.,, O. L. Ittensohn,, V. M. Villarejos,, J. A. Arguedas, and, M. R. Hilleman. 1973. Etiologic relationship of marmoset-propagated CR326 hepatitis A virus to hepatitis in man. Proc. Soc. Exp. Biol. Med. 142:12571267.
76. Rosenblum, L. S.,, M. E. Villarino,, O. V. Nainan,, M. E. Melish,, S. C. Hadler,, P. P. Pinsky,, W. R. Jarvis,, C. E. Ott, and, H. S. Margolis. 1991. Hepatitis A outbreak in a neonatal intensive care unit: risk factors for transmission and evidence of prolonged viral excretion among preterm infants. J. Infect. Dis. 164:476482.
77. Scholz, E.,, U. Heinricy, and, B. Flehmig. 1989. Acid stability of hepatitis A virus. J. Gen. Virol. 70:24812485.
78. Schulman, A. N.,, J. L. Dienstag,, D. R. Jackson,, J. H. Hoofnagle,, R. J. Gerety,, R. H. Purcell, and, L. F. Barker. 1976. Hepatitis A antigen particles in liver, bile, and stool of chimpanzees. J. Infect. Dis. 134:8084.
79. Schultz, D. E.,, C. C. Hardin, and, S. M. Lemon. 1996. Specific interaction of glyceraldehyde 3-phosphate dehydrogenase with the 5′ nontranslated RNA of hepatitis A virus. J. Biol. Chem. 271:1413414142.
80. Schultz, D. E.,, M. Honda,, L. E. Whetter,, K. L. McKnight, and, S. M. Lemon. 1996. Mutations within the 5′ nontranslated RNA of cell culture-adapted hepatitis A virus which enhance cap-independent translation in cultured African green monkey kidney cells. J. Virol. 70:10411049.
81. Shaffer, D. R.,, E. A. Brown, and, S. M. Lemon. 1994. Large deletion mutations involving the first pyrimidine-rich tract of the 5′ nontranslated RNA of hepatitis A virus define two adjacent domains associated with distinct replication phenotypes. J. Virol. 68:55685578.
82. Shaffer, D. R.,, S. U. Emerson,, P. C. Murphy,, S. Govindarajan, and, S. M. Lemon. 1995. A hepatitis A virus deletion mutant which lacks the first pyrimidine-rich tract of the 5′ nontranslated RNA remains virulent in primates after direct intrahepatic nucleic acid transfection. J. Virol. 69:66006604.
83. Siegl, G., and, H. J. Eggers. 1982. Failure of guanidine and 2-(alpha-hydroxybenzyl) benzimidazole to inhibit replication of hepatitis A virus in vitro. J. Gen. Virol. 61:111114.
84. Siegl, G.,, M. Weitz, and, G. Kronauer. 1984. Stability of hepatitis A virus. Intervirology 22:218226.
85. Sjogren, M. H.,, H. Tanno,, O. Fay,, S. Sileoni,, B. D. Cohen,, D. S. Burke, and, R. J. Feighny. 1987. Hepatitis A virus in stool during clinical relapse. Ann. Intern. Med. 106:221226.
86. Skinhoj, P.,, F. Mikkelsen, and, F. B. Hollinger. 1977. Hepatitis A in Greenland: importance of specific antibody testing in epidemiologic surveillance. Am. J. Epidemiol. 105:140147.
87. Snooks, M. J.,, P. Bhat,, J. Mackenzie,, N. A. Counihan,, N. Vaughan, and, D. A. Anderson. 2008. Vectorial entry and release of hepatitis A virus in polarized human hepatocytes. J. Virol. 82:87338742.
88. Stapleton, J. T.,, R. Jansen, and, S. M. Lemon. 1985. Neutralizing antibody to hepatitis A virus in immune serum globulin and in the sera of human recipients of immune serum globulin. Gastroenterology 89:637642.
89. Takeuchi, O., and, S. Akira. 2009. Innate immunity to virus infection. Immunol. Rev. 227:7586.
90. Teixera, M. R., Jr.,, I. V. Weller,, A. Murray,, M. Bamber,, H. C. Thomas,, S. Sherlock, and, P. J. Scheuer. 1982. The pathology of hepatitis A in man. Liver 2:5360.
91. Tesar, M.,, S. A. Harmon,, D. F. Summers, and, E. Ehrenfeld. 1992. Hepatitis A virus polyprotein synthesis initiates from two alternative AUG codons. Virology 186:609618.
92. Tesar, M.,, X. Y. Jia,, D. F. Summers, and, E. Ehrenfeld. 1993. Analysis of a potential myristoylation site in hepatitis A virus capsid protein VP4. Virology 194:616626.
93. Tesar, M.,, I. Pak,, X. Y. Jia,, O. C. Richards,, D. F. Summers, and, E. Ehrenfeld. 1994. Expression of hepatitis A virus precursor protein P3 in vivo and in vitro: polyprotein processing of the 3CD cleavage site. Virology 198:524533.
94. Teterina, N. L.,, K. Bienz,, D. Egger,, A. E. Gorbalenya, and, E. Ehrenfeld. 1997. Induction of intracellular membrane rearrangements by HAV proteins 2C and 2BC. Virology 237:6677.
95. Tjon, G. M.,, R. A. Coutinho,, A. van den Hoek,, S. Esman,, C. J. Wijkmans,, C. J. Hoebe,, B. Wolters,, C. Swaan,, R. B. Geskus,, N. Dukers, and, S. M. Bruisten. 2006. High and persistent excretion of hepatitis A virus in immunocompetent patients. J. Med. Virol. 78:13981405.
96. Umetsu, D. T.,, J. J. McIntire,, O. Akbari,, C. Macaubas, and, R. H. DeKruyff. 2002. Asthma: an epidemic of dysregulated immunity. Nat. Immunol. 3:715720.
97. Vallbracht, A.,, L. Hofmann,, K. G. Wurster, and, B. Flehmig. 1984. Persistent infection of human fibroblasts by hepatitis A virus. J. Gen. Virol. 65:609615.
98. Vento, S.,, T. Garofano,, G. di Perri,, L. Dolci,, E. Concia, and, D. Bassetti. 1991. Identification of hepatitis A virus as a trigger for autoimmune chronic hepatitis type 1 in susceptible individuals. Lancet 337:11831187.
99. Vento, S.,, T. Garofano,, C. Renzini,, F. Cainelli,, F. Casali,, G. Ghironzi,, T. Ferraro, and, E. Concia. 1998. Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C. N. Engl. J. Med. 338:286290.
100. Villarejos, V. M.,, J. Serra,, K. Anderson-Visona, and, J. W. Mosley. 1982. Hepatitis A virus infection in households. Am. J. Epidemiol. 115:577586.
101. Wang, N.,, Y. Liang,, S. Devaraj,, J. Wang,, S. M. Lemon, and, K. Li. 2009. Toll-like receptor 3 mediates establishment of an antiviral state against hepatitis C virus in hepatoma cells. J. Virol. 83:98249834.
102. Wasley, A.,, A. Fiore, and, B. P. Bell. 2006. Hepatitis A in the era of vaccination. Epidemiol. Rev. 28:101111.
103. Werzberger, A.,, B. Mensch,, B. Kuter,, L. Brown,, J. Lewis,, R. Sitrin,, W. Miller,, D. Shouval,, B. Wiens,, G. Calandra,, J. Ryan,, P. Provost, and, D. Nalin. 1992. A controlled trial of a formalin-inactivated hepatitis A vaccine in healthy children. N. Engl. J. Med. 327:453457.
104. Whetter, L. E.,, S. Day,, O. Elroy-Stein,, E. A. Brown, and, S. M. Lemon. 1994. Low efficiency of the 5′ nontranslated region of hepatitis A virus RNA in directing cap-independent translation in permissive monkey kidney cells. J. Virol. 68:52535253.
105. Wünschmann, S.,, B. Becker, and, A. Vallbracht. 2002. Hepatitis A virus suppresses monocyte-to-macrophage maturation in vitro. J. Virol. 76:43504356.
106. Yang, Y.,, Y. Liang,, L. Qu,, Z. Chen,, M. Yi,, K. Li, and, S. M. Lemon. 2007. Disruption of innate immunity due to mitochondrial targeting of a picornaviral protease precursor. Proc. Natl. Acad. Sci. USA 104:72537258.
107. Yang, Y.,, M. Yi,, D. J. Evans,, P. Simmonds, and, S. M. Lemon. 2008. Identification of a conserved RNA replication element (cre) within the 3Dpol-coding sequence of hepatoviruses. J. Virol. 82:1011810128.
108. Yi, M.,, D. E. Schultz, and, S. M. Lemon. 2000. Functional significance of the interaction of hepatitis A virus RNA with glyceraldehyde 3-phosphate dehydrogenase (GAPDH): opposing effects of GAPDH and polypyrimidine tract binding protein on internal ribosome entry site function. J. Virol. 74:64596468.
109. Yotsuyanagi, H.,, S. Iino,, K. Koike,, K. Yasuda,, K. Hino, and, K. Kurokawa. 1993. Duration of viremia in human hepatitis A viral infection as determined by polymerase chain reaction. J. Med. Virol. 40:3538.
110. Zamir, C.,, S. Rishpon,, D. Zamir,, A. Leventhal,, N. Rimon, and, E. Ben-Porath. 2001. Control of a community-wide outbreak of hepatitis A by mass vaccination with inactivated hepatitis A vaccine. Eur. J. Clin. Microbiol. Infect. Dis. 20:185187.

This is a required field
Please enter a valid email address
Please check the format of the address you have entered.
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error